AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BerGenBio

Regulatory Filings Dec 11, 2017

3555_rns_2017-12-11_1516deb7-c224-4642-8cf8-a42b94741edb.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting

BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting

35 relapsed/refractory AML and MDS patients received BGB324 as monotherapy; two

CRi and five PR were observed, and seven patients stayed on treatment for more

than four months. Three novel and proprietary predictive biomarker candidates

were identified.

Bergen, Norway, 11 Dec 2017 - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company focused on developing a pipeline of first-in-class AXL

kinase inhibitors to treat multiple cancer indications, today announced that it

presented an update on the BGBC003 clinical trial (NCT02488408) with selective

AXL inhibitor BGB324 in patients with relapsed/refractory Acute Myeloid

Leukaemia (AML) or Myeloid Dysplastic Syndrome (MDS). Clinical benefit was

observed and three novel, proprietary predictive biomarker candidates were

identified. Data showing the immune modulatory effect of BGB324 in this patient

population was also reported.

In a poster presentation at the 59th American Society of Hematology Annual

Meeting in Atlanta entitled: "The orally available selective AXL inhibitor

BGB324 induces diversification of the immune repertoire and specific changes in

plasma biomarker profiles", Professor Sonja Loges, attending physician at the

University Hospital in Hamburg-Eppendorf and lead investigator of the BGBC003

trial, detailed the following:

· 35 patients with relapsed/refractory AML or MDS received BGB324 monotherapy

on the BGBC003 trial. Two patients achieved complete responses with incomplete

heamatologic recovery (CRi) and five achieved partial responses (PR). Seven

patients reported disease stabilisation for more than four months. Four patients

remain on study at the time of data cut-off.

· Three novel predictive biomarker candidates that correlated significantly

with clinical benefit were detected in blood, bone marrow plasma or bone marrow

cell samples from patients.

· Over the course of treatment with BGB324, patients demonstrated a

diversification of their T- and B-cell receptor repertoire in peripheral blood

and/or bone marrow indicating immune activation upon BGB324 therapy.

Professor Sonja Loges commented: ''Relapsed/refractory AML and MDS patients

currently have no treatment options. Selective AXL inhibition holds particular

promise as a potential new treatment modality as it blocks a key cancer survival

mechanism in the bone marrow and acts as an activator of the immune system. I am

extremely encouraged by these signs of clinical efficacy of BGB324 in these

patients as well as the favourable safety profile observed.''

Richard Godfrey, CEO of BerGenBio commented: "The BGBC003 trial in AML is one of

six ongoing phase II trials evaluating our first-in-class selective AXL

inhibitor BGB324. The observed clinical benefit with BGB324 monotherapy in AML

and MDS is very encouraging. The second part of the trial, featuring expansion

cohorts as a monotherapy as well as in combination with low dose chemotherapy is

ongoing and we are looking forward to reporting an update in 2018. I am

particularly encouraged with the biomarker data as this supports our clinical

development strategy to enrich future clinical trials with patients most likely

to benefit from therapy with BGB324''.

About AML

AML is the most common form of acute leukaemia in adults where malignant AML

blasts interfere with the normal functioning of the bone marrow leading to a

multitude of complications like anaemia, infections and bleeding. AML is

diagnosed in over 20,000 patients in the US annually and is rapidly lethal if

left untreated. Successful treatment typically requires intensive therapy or

bone marrow transplantation, and relapse and resistance are common.

Consequently, there is an urgent need for effective novel therapies in

relapsed/refractory patients, particularly those that are ineligible for

intensive therapy.

About the BGBC003 trial

The BGBC003 trial is a phase Ib/II multi-centre open label study of BGB324 as a

single agent in patients with AML or MDS or in a combination with cytarabine and

decitabine in AML patients. Up to 75 patients will be enrolled at centres in the

US, Norway, Germany and Italy. For more information please access trial

NCT02488408 at www.clinicaltrials.gov.

About the 59th ASH Annual Meeting in Atlanta, GA

The 59th ASH Annual Meeting and Exposition is the most comprehensive haematology

conference worldwide and attracts more than 25,000 haematology professionals

from every subspecialty.

About BerGenBio ASA

BerGenBio ASA is a clinical-stage biopharmaceutical company focused on

developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple

cancer indications. The Company is a world leader in understanding the essential

role of AXL kinase in mediating cancer spread, immune evasion and drug

resistance in multiple aggressive solid and haematological cancers.

BerGenBio's lead product, BGB324, is a selective, potent and orally bio

-available small molecule AXL inhibitor in four Company sponsored Phase II

clinical trials in major cancer indications, with read-outs anticipated in the

second half of 2018. It is the only selective AXL inhibitor in clinical

development.

The Company sponsored clinical trials are:

· BGB324 as a single agent and combination therapy in acute myeloid leukaemia

(AML) / myeloid dysplastic syndrome (MDS)

· BGB324 with TARCEVA® (erlotinib) in advanced EGFR mutation driven non-small

cell lung cancer (NSCLC)

· BGB324 with KEYTRUDA in advanced adenocarcinoma of the lung, and

· BGB324 with KEYTRUDA in triple negative breast cancer (TNBC).

The clinical trials combining BGB324 with KEYTRUDA in adenocarcinoma of the lung

and TNBC are conducted in collaboration with Merck & Co., Inc., Kenilworth,

N.J., USA.

In addition, a number of investigator-sponsored trials are underway, including a

trial to investigate BGB324 with either MEKINIST® (trametinib) plus TAFINLAR®

(dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial combining

BGB324 with docetaxel in advanced NSCLC.

BerGenBio is simultaneously developing a companion diagnostic test to identify

patient subpopulations most likely to benefit from treatment with BGB324. This

will facilitate more efficient registration trials and support a precision

medicine based commercialization strategy.

The Company is also developing a diversified pre-clinical pipeline of drug

candidates, including BGB149, an anti-AXL monoclonal antibody.

For further information, please visit: www.bergenbio.com

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary

of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of

OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a

registered trademark of Novartis International AG and MEKINIST® is a registered

trademark of GSK plc.

- Ends -

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Tom Henrik Sundby

Finance Director, BerGenBio ASA

[email protected]

+47 477 54 415

Media Relations

David Dible, Mark Swallow, Marine Perrier

Citigate Dewe Rogerson

[email protected]

+44 207 638 9571

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

[image]

Talk to a Data Expert

Have a question? We'll get back to you promptly.